| New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis … E Pérez-Persona, MB Vidriales, G Mateo, R García-Sanz, MV Mateos, ... Blood, The Journal of the American Society of Hematology 110 (7), 2586-2592, 2007 | 625 | 2007 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 589 | 2010 |
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Pérez, MA Montalbán, ... Blood, The Journal of the American Society of Hematology 112 (10), 4017-4023, 2008 | 513 | 2008 |
| Rituximab plus lenalidomide in advanced untreated follicular lymphoma F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ... New England Journal of Medicine 379 (10), 934-947, 2018 | 343 | 2018 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ... Blood, The Journal of the American Society of Hematology 119 (3), 687-691, 2012 | 325 | 2012 |
| Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials JJ Lahuerta, B Paiva, MB Vidriales, L Cordón, MT Cedena, N Puig, ... Journal of Clinical Oncology 35 (25), 2900-2910, 2017 | 299 | 2017 |
| Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma B Paiva, J Martinez-Lopez, MB Vidriales, MV Mateos, MA Montalban, ... J Clin Oncol 29 (12), 1627-1633, 2011 | 285 | 2011 |
| Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study E Bachy, JF Seymour, P Feugier, F Offner, A López-Guillermo, D Belada, ... Journal of Clinical Oncology 37 (31), 2815, 2019 | 220 | 2019 |
| R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. A Martín, E Conde, M Arnan, MA Canales, G Deben, JM Sancho, ... Ferrata Storti Foundation, 2008 | 211 | 2008 |
| Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter … E Pérez‐Persona, G Mateo, R García‐Sanz, MV Mateos, N De Las Heras, ... British journal of haematology 148 (1), 110-114, 2010 | 149 | 2010 |
| Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone ML Sanchez, J Almeida, D Gonzalez, M Gonzalez, MA Garcia-Marcos, ... Blood 102 (8), 2994-3002, 2003 | 138 | 2003 |
| Long‐term follow‐up in patients treated with Mini‐BEAM as salvage therapy for relapsed or refractory Hodgkin's disease A Martin, MC Fernandez‐Jimenez, MD Caballero, MA Canales, ... British journal of haematology 113 (1), 161-171, 2001 | 120 | 2001 |
| Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA) E Bachy, V Camus, C Thieblemont, D Sibon, RO Casasnovas, L Ysebaert, ... Journal of Clinical Oncology 40 (3), 242-251, 2022 | 102 | 2022 |
| Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation JA Perez-Simon, A Martin, D Caballero, M Corral, MJ Nieto, M Gonzalez, ... Bone marrow transplantation 24 (12), 1279-1283, 1999 | 101 | 1999 |
| Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and … B Paiva, MC Montes, R García-Sanz, EM Ocio, J Alonso, N de Las Heras, ... Leukemia 28 (1), 166-173, 2014 | 99 | 2014 |
| Validation of the NCCN‐IPI for diffuse large B‐cell lymphoma (DLBCL): the addition of β2‐microglobulin yields a more accurate GELTAMO‐IPI C Montalbán, A Díaz‐López, I Dlouhy, J Rovira, A Lopez‐Guillermo, ... British Journal of Haematology 176 (6), 918-928, 2017 | 97 | 2017 |
| Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients B Paiva, NC Gutierrez, X Chen, MB Vidriales, MÁ Montalbán, L Rosinol, ... Leukemia 26 (8), 1862-1869, 2012 | 93 | 2012 |
| The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients B Paiva, MB Vidriales, G Mateo, JJ Perez, MA Montalbán, A Sureda, ... Blood, The Journal of the American Society of Hematology 114 (20), 4369-4372, 2009 | 91 | 2009 |
| Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS … B Paiva, M Pérez-Andrés, MB Vidriales, J Almeida, N de Las Heras, ... Leukemia 25 (4), 697-706, 2011 | 88 | 2011 |
| Plitidepsin: design, development, and potential place in therapy S Alonso-Álvarez, E Pardal, D Sánchez-Nieto, M Navarro, MD Caballero, ... Drug Design, Development and Therapy, 253-264, 2017 | 87 | 2017 |
